- Seldinafil [Viagra]
- Tadalafil [Adcirca, Cialis]
- Vardenafil [Staxyn, Levitra]
- Avanafil [Stendra]
- Others
Erectile Dysfunction Treatment Market size was valued at USD 3612.05 million in 2022 and is expected to reach USD 5951.36 million by 2029, at a CAGR of 7.1% from 2023-2029. The inability to achieve or sustain a firm adequate penile erection during intercourse is referred to as erectile dysfunction. In guys, it is the most frequent sexual health disorder. Stress has an impact on the patient's physical and psychological well-being. Physiological causes such as high blood pressure, high cholesterol, obesity, diabetes, smoking or tobacco use, and psychological ones such as stress, depression, mental health disorders, and so on cause erectile dysfunction. A key element driving the growth of the market for erectile dysfunction treatments is the increase in the number of individuals suffering from erectile dysfunction. Diabetes, renal disease, prostate cancer, high blood pressure, and physical injury to the prostate, penis, and pelvis can all contribute to the condition. Erectile dysfunction can also be caused by emotional and psychological difficulties like sadness, stress, and worry. Prescription pharmaceuticals such as antidepressants, opioid pain relievers, chemotherapeutic agents, hormone therapies, amphetamines, and several sleeping prescriptions might also contribute to this disease. this report studies global Market dynamics elaborately to identify the current trends & drivers, future opportunities, and possible challenges to the key stakeholders operating in the market. In addition, The global Erectile Dysfunction Treatment Market report includes human demographics; regulatory scenario, and competition analysis with a vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed the global Erectile Dysfunction Treatment Market to better equip clients with possible investment opportunities across the regions (regional Investment hot spots) and market unmet needs (Product opportunities).
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The rise in the number of people suffering from erectile dysfunction is a primary factor driving the global erectile dysfunction therapy market. According to statistics, one out of every ten males in the world suffers from ED. Over 30 million men in the United States alone suffer from ED, and the figure is anticipated to climb in the coming years. Men between the ages of 20 and 29 had a 65 percent likelihood of having ED, compared to older men aged 75 and up, who have a 77.5 percent chance of having ED.
The erectile dysfunction treatment market size was valued at USD 3612.05 million in 2022
The erectile dysfunction treatment market's key players are: Pfizer, Inc. (U.S) Bayer AG (Germany) Eli Lilly and Company (U.S) Apricus Biosciences Inc. (U.S) Meda Pharmaceuticals, Inc. (U.S) K. Chemicals Co. Ltd.(Korea) Vivus, Inc. (U.S) Dong-A ST (South Korea)
The erectile dysfunction treatment market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
1. Executive Summary |
2. Global Erectile Dysfunction Treatment Market Introduction |
2.1.Global Erectile Dysfunction Treatment Market - Taxonomy |
2.2.Global Erectile Dysfunction Treatment Market - Definitions |
2.2.1.Product Type |
2.2.2.Distribution Channel |
2.2.2. |
2.2.3.Region |
3. Global Erectile Dysfunction Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID-19 on Market |
4. Global Erectile Dysfunction Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Erectile Dysfunction Treatment Market By Product Type , 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. Seldinafil [Viagra] |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Tadalafil [Adcirca, Cialis] |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Vardenafil [Staxyn, Levitra] |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Avanafil [Stendra] |
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Others |
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
6. Global Erectile Dysfunction Treatment Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. Hospitals |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Clinics |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Others |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.3.3. Global Erectile Dysfunction Treatment Market By , 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7. Global Erectile Dysfunction Treatment Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific (APAC) |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Middle East and Africa (MEA) |
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Latin America |
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8. North America Erectile Dysfunction Treatment Market,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.Seldinafil [Viagra] |
8.1.2.Tadalafil [Adcirca, Cialis] |
8.1.3.Vardenafil [Staxyn, Levitra] |
8.1.4.Avanafil [Stendra] |
8.1.5.Others |
8.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Hospitals |
8.2.2.Clinics |
8.2.3.Others |
8.2. Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1.United States of America (USA) |
8.3.2.Canada |
9. Europe Erectile Dysfunction Treatment Market,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Seldinafil [Viagra] |
9.1.2.Tadalafil [Adcirca, Cialis] |
9.1.3.Vardenafil [Staxyn, Levitra] |
9.1.4.Avanafil [Stendra] |
9.1.5.Others |
9.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Hospitals |
9.2.2.Clinics |
9.2.3.Others |
9.2. Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Germany |
9.3.2.France |
9.3.3.Italy |
9.3.4.United Kingdom (UK) |
9.3.5.Spain |
9.3.6.Rest of EU |
10. Asia Pacific (APAC) Erectile Dysfunction Treatment Market,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Seldinafil [Viagra] |
10.1.2.Tadalafil [Adcirca, Cialis] |
10.1.3.Vardenafil [Staxyn, Levitra] |
10.1.4.Avanafil [Stendra] |
10.1.5.Others |
10.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Hospitals |
10.2.2.Clinics |
10.2.3.Others |
10.2. Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.China |
10.3.2.India |
10.3.3.Australia and New Zealand (ANZ) |
10.3.4.Japan |
10.3.5.Rest of APAC |
11. Middle East and Africa (MEA) Erectile Dysfunction Treatment Market,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Seldinafil [Viagra] |
11.1.2.Tadalafil [Adcirca, Cialis] |
11.1.3.Vardenafil [Staxyn, Levitra] |
11.1.4.Avanafil [Stendra] |
11.1.5.Others |
11.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Hospitals |
11.2.2.Clinics |
11.2.3.Others |
11.2. Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.GCC Countries |
11.3.2.South Africa |
11.3.3.Rest of MEA |
12. Latin America Erectile Dysfunction Treatment Market,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Seldinafil [Viagra] |
12.1.2.Tadalafil [Adcirca, Cialis] |
12.1.3.Vardenafil [Staxyn, Levitra] |
12.1.4.Avanafil [Stendra] |
12.1.5.Others |
12.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Hospitals |
12.2.2.Clinics |
12.2.3.Others |
12.2. Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Brazil |
12.3.2.Mexico |
12.3.3.Rest of LA |
13. Competition Landscape |
13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
13.2.1.Pfizer, Inc. (U.S) |
13.2.2.Bayer AG (Germany) |
13.2.3.Eli Lilly and Company (U.S) |
13.2.4.Apricus Biosciences Inc. (U.S) |
13.2.5.Meda Pharmaceuticals, Inc. (U.S) |
13.2.6.K. Chemicals Co. Ltd.(Korea) |
13.2.7.Vivus, Inc. (U.S) |
13.2.8.Dong-A ST (South Korea) |
14. Research Methodology |
15. Appendix and Abbreviations |